Poor market prospects are the largest negative factor currently weighing against this company. The company has executed a couple of strategic pivots recently, which have so far left it without a clear viable product, nor a rapid path to developing one. The founder's initial vision, from inception in 2011 until roughly late 2020 / early 2021, was to develop genetically engineered E. Coli cell lines that could disrupt the biologics manufacturing market by expressing therapeutic proteins more efficiently than existing solutions (e.g., such as mammalian cells like CHO). But around 2020-2021, the company began to shift strategy toward using its E. Coli technology to produce in-house data to train deep learning AI models in pursuit of AI-directed biologic drug development. Ideally this would be monetized through a series of drug development partnerships or contract research arrangements with other pharmaceutical firms. However, the company's AI technology is still relatively new, and from a commercial standpoint not yet well proven, so in addition to external partnerships opportunities, the company is also considering development of internal lead candidate molecules as well, hoping to complete an IND filing and/or Phase I Clinical Trial before running through the remaining investor capital still leftover from the IPO in mid-2021. Both of these paths to a viable business model (either external co-development partnerships, or internal drug candidates) are likely to be lengthy and difficult, with success uncertain. Aside from poor market prospects, an additional side issue is that the founder / CEO may no longer be the best qualified person to lead the company. His core technical expertise is synthetic biology, genetic engineering, and cell culture. But now the company has refashioned itself into an AI drug development firm, it's not clear why he's still in command, as he does not have significant prior career experience in either deep learning AI or the pharmaceutical clinical development cycle. He's arguably overdue to be transitioned out of his role, however the board does not yet seem to have arrived at this same conclusion. For a prospective new hire considering a role here, a key practical concern is that the company may run out of existing capital before a viable product (either a well proven AI-driven consulting/partnership model with external firms, or an internal therapeutic candidate) is developed. If this happens, it could prove difficult to raise a new round of additional capital, and the company would likely respond by eliminating many roles and shrinking its headcount, potentially meaning that a new hire might not work here for very long. If you're thinking of quitting your job in a year anyway to return to grad school, or if you're already jobless and the prospect of unstable employment therefore presents little additional risk to you, I'd heartily recommend this company as a great place to work. The day to day experience is too good to pass up. But for all others, on balance I'd advise caution before abandoning a secure paycheck to come here.
